SAB Biotherapeutics Inc SABS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $3.06
- Day Range
- $2.96–3.12
- 52-Week Range
- $1.97–5.15
- Bid/Ask
- $2.85 / $3.27
- Shares Outstanding
- 90.99M
- Market Cap
- $271.14M
- Volume/Avg
- 416,318 / 488,195
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
SAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The company's lead product candidate, SAB-142, targets autoimmune Type 1 Diabetes (T1D) with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. It is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 86
- Website
- https://www.sab.bio
Valuation
|
Metric
|
SABS
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.16 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
SABS
Financial Strength
|
Metric
|
SABS
|
|---|---|
Quick Ratio | 8.93 |
Current Ratio | 9.22 |
Interest Coverage | −71.87 |
Quick Ratio
SABS
Profitability
|
Metric
|
SABS
|
|---|---|
Return on Assets (Normalized) | −30.27% |
Return on Equity (Normalized) | −34.29% |
Return on Invested Capital (Normalized) | −35.44% |
Return on Assets
SABS
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|DGwW%# | LOCK|cWGS# | $128B | |||
| Moderna Inc
MRNA
| LOCK|gxcb!&< | LOCK|W!r | $76B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|LH#lY&y | LOCK|@RYJS | $76B | |||
| argenx SE ADR
ARGX
| LOCK|>H<>lg | LOCK|!M | $57B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|l!X!V>m | LOCK|!h | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|!#L?YD | LOCK|m?@J | $29B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|G?fZ>@>f | LOCK|%jxv | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|&xphx$ | LOCK|?jJ | $24B | |||
| Incyte Corp
INCY
| LOCK|<wBgRRb | LOCK|$$? | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|<wG?l&p | LOCK|^R | $15B |
United States